We serve Chemical Name:3-(3,4-dichlorophenyl)-9-methyl-3,9-diazaspiro[5.5]undecane CAS:918653-18-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![3-(3,4-dichlorophenyl)-9-methyl-3,9-diazaspiro[5.5]undecane](https://a.dearchem.com/CAS2/918653-18-6.png)
Chemical Name:3-(3,4-dichlorophenyl)-9-methyl-3,9-diazaspiro[5.5]undecane
CAS.NO:918653-18-6
Synonyms:3,9-Diazaspiro[5.5]undecane,3-(3,4-dichlorophenyl)-9-methyl;3-(3,4-dichloro-phenyl)-9-methyl-3,9-diaza-spiro[5.5]undecane
Molecular Formula:C16H22Cl2N2
Molecular Weight:313.26500
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:6.48000
Exact Mass:312.11600
LogP:4.30850
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3,9-Diazaspiro[5.5]undecane,3-(3,4-dichlorophenyl)-9-methyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(3,4-dichloro-phenyl)-9-methyl-3,9-diaza-spiro[5.5]undecane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(3,4-dichloro-phenyl)-9-methyl-3,9-diaza-spiro[5.5]undecane Use and application,3,9-Diazaspiro[5.5]undecane,3-(3,4-dichlorophenyl)-9-methyl technical grade,usp/ep/jp grade.
Related News: The three products for which it received the PLI approvals are betamethasone with a production capacity of 12 MT at an investment of Rs 31.43 crore, dexamethasone of 10 MT with an investment of Rs. 26.19 crore and prednisolone of 15 MT at Rs 39. 29 crore. This takes the total investment to Rs 96.91 core. 2-(histidyl-amino)-butyric acid manufacturers Charles River looks forward to continuing its ongoing partnership with AstraZeneca. It was great to join the team today, to see the facility for myself and congratulate them on this really significant expansion, which will see an €8m investment, creating 90 new jobs for Mayo. 9H-Thioxanthene-9-carboxamide, N,9-dipropyl- suppliers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit methyl(propan-2-yloxy)phosphinic acid,thorium vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit methyl(propan-2-yloxy)phosphinic acid,thorium vendor & factory.
